Skip to content

Transvaginal Human Acellular Dermal Matrix for Prolapse Treatment

Transvaginal Human Acellular Dermal Matrix and Sacrospinous Fixation for Anterior and Apical Prolapse Treatment in Patients With Hiatal Ballooning or Levator Ani Injury: a Randomized Pilot Trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06404931
Enrollment
90
Registered
2024-05-08
Start date
2024-07-01
Completion date
2026-01-01
Last updated
2025-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prolapse; Female, Prolapse Genital, Prolapse Uterovaginal

Brief summary

This is a randomised study in which we compare the effectiveness of three different procedures in mending symptomatic anterior and apical prolapse in patients who are candidates to receive surgery. They will be randomly assigned in a ratio 1:1:1 to three different groups who will have assigned three different kinds of surgery. In the patients of the first group a classic vaginal hysterectomy with anterior colporrhaphy will be practised. Patients who belong to group two will undergo a vaginal hysterectomy followed by placement of an acellular dermal matrix from cadaveric donors (hADM) for anterior reinforcement and sacrospinous fixation with Anchorsure® device (Neomedic trade mark (TM) International, Spain). Finally, patients from group three will have vaginal hysterectomy followed by sacrospinous fixation with Anchorsure® alone . Patients will be followed-up at 4 weeks, 6 months, 12 months and annually till 36 months to evaluate relapses and possible complications.

Detailed description

Eligible patients will be women with symptomatic anterior and apical prolapse with hiatal ballooning or levator ani injury eligible for vaginal surgical treatment. At the time of the indication for surgery, anatomical severity of the prolapse (according to the Pelvic Organ Prolapse Quantification System (POP-Q) scale) and the symptoms of prolapse and sexual function, as well as their impact on the quality of life of the patient, are evaluated using validated questionnaires Pelvic Floor Impact Questionnaire (PFIQ), Pelvic organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)and European Quality of Life-5 Dimensions Questionnaire (EQ5D). Anatomical severity of the prolapse will be also evaluated by ecography described as follows. Three-dimensional 3D/4D transperineal ultrasound (TPS) will be performed using a GE Voluson® ultrasound system (GE Medical Systems) with a RAB 8-4-MHz transducer at an acquisition angle of 85°. TPS will be performed with the probe covered with a powder-free glove and applied in the midsagittal plane to the introitus using moderate pressure. Volumes are acquired at rest, on maximum pelvic floor muscle contractility and during maximal Valsalva maneuver. Patients perform Valsalva for at least 5 s, and the best of three volumes is used for analysis. Using visual biofeedback, an attempt is made to correct for levator co-activation by requesting the women observe the narrowing and widening of the levator hiatus during the maneuvers. 3D volumes are measured offline using GE 4 Dimension View (GE Medical Systems). Using the best Valsalva maneuver, pelvic organ descent measurements are obtained relative to a horizontal line from the inferior margin of the pubic symphysis. Levator hiatal area is assessed in the plane of minimal hiatal dimensions. Surgical indication will be determined by gynaecologists and the decision will be clearly dissociated from the decision of study inclusion. Therefore, the performance of the study should not modify the habits of surgical indication by the doctors. The study will be a single-blinded study, as it is impossible to blind the health care workers involved for the surgical procedure to which the woman is randomized. The physician evaluating the patients during the follow-up will be blinded about the group the patients were randomized to. Women will be randomly assigned after consenting for participation in the study, by means of an interactive response technology system in a 1:1:1 ratio to receive surgical treatment with vaginal hysterectomy followed by hADM anterior reinforcement and sacrospinous fixation with Anchorsure® device (NeomedicTM International, Spain), vaginal hysterectomy followed by sacrospinous fixation with Anchorsure® alone or classic vaginal hysterectomy with anterior colporrhaphy. A sacrospinous fixation-alone group was included to assess the impact of this technique in the principal surgery group. Patients will be followed-up at 4 weeks, 6 months, 12 months and annually till 36 months. Anatomical results will be evaluated by a member of the team blinded to the surgery performed during follow-up visits after surgery and by 3D ultrasound of the pelvic floor. Functional results are evaluated using the validated questionnaires performed prior to surgery done by the patients during follow-up visits after surgery.

Interventions

PROCEDUREVaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device

Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device

PROCEDUREVaginal hysterectomy plus anterior colporrhaphy

Vaginal hysterectomy plus anterior colporrhaphy

PROCEDUREVaginal hysterectomy plus sacrospinous fixation with Anchorsure® device

Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device

Sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
CollaboratorOTHER
Germans Trias i Pujol Hospital
CollaboratorOTHER
Hospital Arnau de Vilanova
CollaboratorOTHER
Hospital Mutua de Terrassa
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Women with symptomatic POP with indication of vaginal surgery. * Women with hiatal ballooning or levator ani injury evaluated by 3D pelvic floor ultrasound. * Women ≥18 years old. * Women wishing to complete a 36-month follow-up. * Understand and accept the study procedures and sign the informed consent.

Exclusion criteria

* Women with previous pelvic floor or prolapse surgery * Women with POP grade IV * Women with chronic pelvic pain. * Not being able to understand the nature of the study and/or the procedures to be followed. * Not signing the informed consent

Design outcomes

Primary

MeasureTime frameDescription
Recurrence of anatomical anterior vaginal wall prolapse36 monthsDefined as point Ba POP-Q stage ≥II by clinical examination

Secondary

MeasureTime frameDescription
Differences between groups in symptomatic recurrence36 monthsEvaluated by Pelvic Floor Impact Questionnaire. Minimum value: 0. Maximum value: 300. The higher the value worse is the outcome
Differences between groups in quality of Life36 monthsEvaluated by European Quality of Life-5 Dimensions Questionnaire. Minimum value: 0. Maximum value: 1. The higher the value the worse is the outcome
Differences between groups in sexual functioning.36 monthsEvaluated by Pelvic organ Prolapse/Urinary Incontinence Sexual Questionnaire. Minimum value: 0. Maximum value: 100. The higher the value the worse is the outcome
Difference between groups in anatomical prolapse36 mothsDefined as point C POP-Q stage ≥II by clinical examination
Differences between groups in operative time36 monthsEvaluated by minutes of duration of surgery
Differences between groups in surgical complication rate.36 monthsMonitoring of development of hematoma, urologic lesion, need for blood transfusion, suture dehiscence, pain, infection and mesh extrusion
Differences between groups in reintervention rate36 monthsReintervention will be done in cases of symptomatic recurrence of the compartment previously treated or development of another prolapse.
Differences between groups in hospital stay36 monthsEvaluated by number of days of hospital stay

Countries

Spain

Contacts

Primary ContactGerard Molina
+34937365050
Backup ContactPilar Arcusa
+34937365050

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026